Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bruce Brent

Cardiovascular Disease San Francisco, CA Medical Doctor

NPI 1093726879 CMS profile 230382

2100 Webster St, Suite 516, San Francisco, CA 94115

Open in the dashboard

General payments

$17,949

290 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bruce Brent of San Francisco, CA is reported in the CMS Open Payments database as having received $17,949 across 290 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $283 3
2024 General $175 1
2023 General $210 1
2022 General $734 7
2021 General $703 18
2020 General $1,213 63
2019 General $14,632 197

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bruce Brent
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Bruce Brent were reported at $283. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Bruce Brent Cardiovascular Disease median Middle half National median
2019 $14,632 $450 $127–$1,392 $163
2020 $1,213 $242 $77–$751 $114
2021 $703 $335 $101–$1,037 $132
2022 $734 $395 $121–$1,211 $149
2023 $210 $443 $136–$1,283 $160
2024 $175 $450 $136–$1,323 $164
2025 $283 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $10,514 51 payments
  2. Medtronic, Inc. $1,122 9 payments
  3. Medtronic Vascular, Inc. $962 10 payments
  4. Amgen Inc. $729 25 payments
  5. Philips Electronics North America Corporation $533 2 payments
  6. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $522 29 payments
  7. HeartFlow, Inc. $473 6 payments
  8. Pfizer Inc. $408 19 payments
  9. Astellas Pharma US Inc $281 10 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $268 14 payments
  11. Other $2,138 115 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,400 5 payments
  2. Food and Beverage $7,722 278 payments
  3. Travel and Lodging $668 3 payments
  4. Education $105 3 payments
  5. Grant $55 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $10,472 48 payments
  2. Resolute $779 8 payments
  3. Repatha $641 24 payments
  4. SYMPLICITY G3 $560 3 payments
  5. LifeVest $522 29 payments
  6. Spectranetics Undiv $500 1 payment
  7. FFRct $449 4 payments
  8. ELIQUIS $408 19 payments
  9. ONYX FRONTIER $386 3 payments
  10. Corlanor $275 10 payments
  11. Other $3,453 166 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

5,958

Median for Cardiology: 2,533

Drug cost

$1,137,454

Median for Cardiology: $485,213

Branded share of claims

20.3%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 431 $512,499
Repatha Sureclick Evolocumab Brand 208 $160,425
Xarelto Rivaroxaban Brand 115 $148,004
Jardiance Empagliflozin Brand 72 $72,449
Entresto Sacubitril/Valsartan Brand 48 $63,765
Praluent Pen Alirocumab Brand 62 $57,732
Ezetimibe Generic 794 $23,183
Nexlizet Bempedoic Acid/Ezetimibe Brand 18 $14,508
Farxiga Dapagliflozin Propanediol Brand 12 $13,536
Ranolazine Er Ranolazine Brand 77 $11,618

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$253,111

Of which drugs: $1,994

Medicare patients

902

Average age 77

Services billed

3,142

374 women, 528 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Arthritis 41%
Atrial fibrillation 37%
Chronic kidney disease 29%
Heart failure 28%
Diabetes 27%
Cancer 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 35 140 $1,091
Injection, perflutren lipid microspheres, per ml Q9957 Office 15 27 $899

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

290 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record